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ABSTRACT
Introduction People receiving haemodialysis experience 
a high symptom burden and impaired quality of life. The 
use of patient- reported outcome measures (PROMs) is 
increasing in nephrology care, however their acceptability, 
utility and impacts are not well understood.
Methods and analysis We describe a protocol for 
a qualitative study to evaluate the feasibility and 
acceptability of electronic- PROMs (e- PROMs) data 
capture and feedback in haemodialysis following the pilot 
Symptom monitoring WIth Feedback Trial (SWIFT). SWIFT 
involves linkage of e- PROMs data, including symptoms 
and health- related quality of life, to the Australia and New 
Zealand Dialysis and Transplant Registry with feedback to 
patients’ treating nephrologists and nurse unit managers. 
Focus groups and semistructured interviews will be 
conducted with nephrologists (n=15), dialysis nurses 
(n=24) and patients receiving haemodialysis (n=24) from 
six dialysis units in Australia. Question topics will include 
the technical and clinical feasibility and acceptability of e- 
PROMs reporting and feedback (including the barriers and 
enablers to uptake) and perceived impact on patient care 
and outcomes. Transcripts will be analysed thematically 
and guided by Normalisation Process Theory.
Ethics and dissemination Ethics approval was obtained 
from the relevant hospital Human Research Ethics 
Committees (HREC/18/CALHN/481; HREC/MML/54599). 
The findings from the SWIFT pilot and qualitative 
evaluation will inform the implementation of the SWIFT 
main trial, and more broadly, the use of e- PROMs in 
clinical settings and registries.
Trial registration number ANZCTRN12618001976279.
INTRODUCTION
More than 3 million people worldwide receive 
treatment for kidney failure and numbers are 
expected to rise sharply due to population 
growth and increasing prevalence of diabetes 
and cardiovascular comorbidities.1 Haemodi-
alysis remains the most common treatment 
modality for kidney failure, including 10 983 
Australians and 1978 New Zealanders.2 While 
haemodialysis can prolong life, patients expe-
rience burdensome symptoms3–6 including 
pain, fatigue, itch, nausea, sleep difficulties 
and depression,3 that impair quality of life. 
Quality of life among people on facility- based 
haemodialysis, as measured by standard self- 
report measures such as the EuroQOL 5 
dimensions 5 levels (EQ- 5D- 5L), has shown 
to be around 59% of full health, with a large 
meta- analysis reporting a minimum of 42% of 
Strengths and limitations of this study
 ► Qualitative methods will obtain diverse, detailed 
and in- depth insights into the processes involved in 
electronic patient- reported outcome measures (e- 
PROMs) integration in nephrology care.
 ► Barriers and enablers to the use of e- PROMs in clin-
ical care, and perceived impacts on patient care and 
outcomes, as well as to health professionals will be 
explored alongside a 6- month pilot study.
 ► Findings from this qualitative analysis will help re-
fine the main Symptom monitoring WIth Feedback 
Trial, to improve acceptability and ease of delivery 
of the intervention.
 ► Views and perspectives from a range of stakehold-
ers including patients, nurses and nephrologists will 
be sought.
 ► Evaluation of the pilot study is limited to six nephrol-
ogy centres in two states in Australia and therefore 
findings may not be transferable or identify issues 
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full health.5 This is lower than that among people with 
metastatic prostate cancer and of those with paralysis due 
to spinal cord injury.6
Studies have largely focused on biochemical markers 
of health and survival, while patient- important outcomes 
including symptom burden and quality of life are infre-
quently reported.7–9 In addition to measures of morbidity 
and mortality, dialysis adequacy based on clearance of 
small molecules, particularly urea, has been the biochem-
ical marker of choice for researchers and dialysis clini-
cians.7 9 Notwithstanding the lack of an evidentiary basis 
for an association of biochemical markers with quality of 
life, these markers may be irrelevant to patients receiving 
dialysis as they do not fully capture their experiences and 
perspectives of health and care.
Patient- reported outcome measures (PROMs) assess 
outcomes that reflect how patients feel and function, as 
reported directly from the patient without interpretation 
from others.10 In primary care and oncology settings, 
collecting and providing PROMs to health professionals 
has shown benefits including identifying unmet patient 
physical and psychological needs, enhancing patient–
provider communications and shared decision- making 
and improved quality of care.10 Findings from two 
randomised trials in oncology also suggest symptom moni-
toring improves patient quality of life and survival.11–13 
There is a dearth of evidence on the systematic measure-
ment of and response to symptom burden among people 
receiving dialysis, representing potential missed opportu-
nities to improve patient care, quality of life and survival, 
particularly given the severity of symptoms for these 
patients.
A recent prospective cross- sectional survey of 79 dialysis 
units in Australia and New Zealand showed that 55 of 79 
units (70%) collected PROMs or patient- reported expe-
rience measures.14 The Integrated Palliative Outcome 
Scale- Renal (IPOS- Renal) was the most commonly 
reported instrument to measure symptoms (40% of 
units) and the EQ- 5D- 5L for the assessment of quality 
of life (24%). Insufficient time and staff resources were 
identified as the main barriers to collection of PROMs 
(19 out of 24 units (79%)).
The Australia and New Zealand Dialysis and Transplant 
Registry (ANZDATA) is a clinical quality registry estab-
lished in 1977 in which clinical and laboratory data are 
held on people receiving dialysis or kidney transplan-
tation (eg, mortality, comorbidities, treatments, dial-
ysis adequacy). While clinical quality registries such as 
ANZDATA serve to assess the quality of clinical care in 
order to improve patient outcomes, they do not gener-
ally collect PROMs.15 16 Linkage of PROMs data with 
an already established clinical and treatment registry 
(ANZDATA) represents a method of combining data that 
is potentially meaningful to both health professionals and 
patients, including aspects of patient well- being and care.
In line with patient priorities,9 use of PROMs is being 
increasingly encouraged in nephrology, but knowledge 
on how to effectively implement PROMs collection to 
improve routine clinical practice is limited. One theory 
that can guide understanding of the required behaviour 
change to incorporate electronic PROMs collection into 
routine care, and take action based on these data, is 
Normalisation Process Theory (NPT). This theory aims 
to explain the factors needed for successful implementa-
tion and integration of interventions into routine work, 
and is easily applied to the use of technology in health-
care settings. Using NPT as a framework for analysis of 
qualitative data in a pilot study can improve the design of 
trials with a complex intervention by highlighting poten-
tial problems with recruitment or data collection. It also 
facilitates analysis of the potential benefits and harms 
of providing symptom information to clinicians and the 
impact of this data on patient care and outcomes.
In addition, the potential benefits and harms of 
providing symptom information to members of the 
patients’ treating team on patient care and outcomes are 
unknown. The aim of the main Symptom monitoring 
WIth Feedback Trial (SWIFT) is to assess the clinical 
and cost- effectiveness of regular symptom monitoring in 
people receiving in- centre haemodialysis with feedback 
to clinicians, embedded within ANZDATA. In prepara-
tion for the main trial, the SWIFT pilot study is being 
conducted in six Australian dialysis centres in Queensland 
and South Australia to evaluate the technical and clinical 
feasibility and acceptability of this intervention. Here 
we describe the protocol for a qualitative study to eval-
uate the SWIFT pilot study. Following the completion of 
the SWIFT pilot study, focus groups and semistructured 
interviews with patients, nurses and nephrologists will 
specifically address the questions of how acceptable and 
feasible it is to collect, interpret and act on electronic- 
PROMs (e- PROMs) including quality of life and symptom 
burden; and why (or why not) the provision of symptom 
information changes clinician–patient conversations and 
care. This study will also uncover the perceived impact 
of e- PROMS collection and feedback on patient care and 
outcomes, as described by those who are at the coalface of 
their delivery and use.
METHODS AND ANALYSIS
This study is informed by the UK Medical Research 
Council Guidance for Process Evaluation17 and will be 
reported in accordance with the Consolidated Criteria 
for Reporting Qualitative Research.18
Context: SWIFT pilot study
Setting
Four South Australian dialysis centres and two Queensland 
dialysis centres in Australia will participate in the SWIFT 
pilot study. The centres are of varying sizes, cover hetero-
geneous socioeconomic populations and geographical 
areas and have different models of care, reflecting real- 
world variations in practice and haemodialysis service 
delivery. At the time of the SWIFT pilot study, approxi-
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these centres. Centre- based consent for the pilot was 
obtained with a patient- based opt- out option to minimise 
selection bias. PROMs data collection for the SWIFT pilot 
is scheduled to complete in April 2020.
SWIFT intervention
Design
Sites will be randomly allocated to either the interven-
tion arm (3- month symptom monitoring with feedback 
to clinicians) or the non- intervention arm (quality of life 
collection only). E- PROMs will be collected via a tablet 
(Samsung Galaxy Tab A V.10.5) at patients’ in- centre 
haemodialysis appointments either before, during or after 
dialysis. For all sites, quality of life will be measured using 
the EQ- 5D- 5L19 at baseline and 6 months. For those in 
the intervention arm, symptom burden will be measured 
using the IPOS- Renal20 at baseline, 3 and 6 months. These 
instruments were chosen for several reasons including 
familiarity with their use as identified in our prior national 
audit, validation in Australian patients on dialysis, accept-
ability to patients and sensitivity to the changes in quality 
of life likely to be brought about through comprehensive 
symptom management.14 20–22
Administration and data collection
Nurse unit managers of participating sites will be 
provided Quick Response codes unique to each patient, 
a tablet and user guides with e- PROMs administration 
instructions. Clinical nurses involved in the patients’ care 
will be responsible for preparing the tablet, providing it 
to patients and cleaning it after use according to local 
infection- control policies. Patients will be encouraged to 
complete the questions honestly and without input from 
others. All dialysis nursing staff will have attended 1–2 
training sessions giving information about the study, the 
purpose of collecting PROMs, and for those in the inter-
vention arm, the process for interpreting IPOS- Renal 
symptom scores.
E-PROMs feedback
E- PROMs data will be stored temporarily on the tablets and 
then transferred periodically to specific database tables 
in the ANZDATA Registry. Tailored emails containing 
the individual patient’s IPOS- Renal scores will be gener-
ated and sent by ANZDATA staff to the dialysis nurse 
unit manager and to the patient’s treating nephrologist, 
with patients reporting scores of 3 (severe symptoms) or 
4 (overwhelming symptoms) highlighted in the body of 
the email. In this email, clinicians will be encouraged to 
discuss symptoms with their patients at their next clinical 
encounter and will be provided with an attached docu-
ment including hyperlinks to evidence- based symptom 
management guidelines.
Qualitative evaluation
The schema of the qualitative evaluation of the SWIFT 
pilot is provided in figure 1. Qualitative methods will 
be used to elicit the experiences and perspectives of 
patients, nurse unit managers, nursing staff and nephrol-
ogists regarding the intervention process, acceptability 
and feasibility, and perceived impacts on patient care 
and outcomes. The findings will inform refinement of 
the intervention processes for the main SWIFT trial and 
reveal how this system may be implemented into routine 
care for people receiving haemodialysis.
Participant selection and recruitment
Patients
Eligible participants will be English- speaking patients or 
those with an interpreter available, ≥18 years, who are 
able to provide informed consent and who completed the 
IPOS- Renal and/or the EQ- 5D- 5L at 6 months. A purpo-
sive sampling strategy will be applied to capture a diverse 
range of patient experiences and perspectives in focus 
groups and interviews, based on demographic (sex, age, 
ethnicity and linguistic background) and clinical factors 
(time since haemodialysis commencement and symptom 
burden severity). As interviews are being completed, we 
will monitor the demographic and clinical characteristics 
to ensure to target recruitment to include any ‘missing’ 
characteristics. Patients participating in the SWIFT pilot 
study will be offered information about the qualitative 
evaluation component by nursing staff, who will then 
Figure 1 Qualitative evaluation study schema. e- PROMs, electronic- patient- reported outcome measures; SWIFT, Symptom 
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put forward interested patients to the research team. 
A member of the research team will contact potential 
participants, explain the purpose of the interview or focus 
group and invite them to participate. It will be empha-
sised that participation is voluntary and that participants 
have the right to withdraw at any time without having 
to provide a reason. Those who express interest will be 
provided a participant information sheet and consent 
form specific to the qualitative study and then followed 
up for consenting and formal arrangement of the inter-
view or focus group.
Nurse unit managers and nurses
Nurse unit managers and nursing staff at participating 
sites will be eligible to participate in a semistructured 
interview or focus group. All dialysis nursing staff will 
be informed of the qualitative component of the SWIFT 
pilot study and those interested will be put forward to 
the research team by the nurse unit manager. Purposive 
sampling will ensure nurses of varying ages with different 
roles and experience and from both arms of the trial are 
captured. Views of nurses not involved in administra-
tion of e- PROMs in their unit will also be sought, to also 
understand symptom management practices in standard 
care. Standard consenting processes as described above, 
will be followed.
Nephrologists
Nephrologists eligible to participate in an interview will 
be those with patients in either study arm, as well as 
nephrologists not participating in the pilot study from 
an additional centre in South Australia, to explore 
processes and practices of symptom management in stan-
dard care. Purposive sampling will ensure nephrologists 
of diverse age, sex, level of experience and practice site 
are included. Nephrologists of participating sites in the 
SWIFT pilot study who received e- PROMs data indicating 
severe or overwhelming symptoms in their patients, as 
well as those who did not, will be interviewed to gather 
diverse perspectives. A member of the research team will 
contact nephrologists, explain the purposes of the inter-
view and invite them to participate. Standard consenting 
processes as described above, will be followed. Patients 
will be reimbursed with a gift card to the value of $50. No 
reimbursement will be provided to health professionals.
Data collection
Interviews and focus groups with patients, nurses and 
nephrologists are scheduled to commence in April 2020 
and completed by July 2020 within approximately 4 weeks 
of centres completing the 6- month data collection. This 
timeframe was believed to be critical to ensuring partic-
ipants’ accurate recall of their experiences in the trial 
and allowing opportunity for patients of sites in the inter-
vention arm of the pilot to have had contact with their 
treating nephrologist, for potential actioning of symptom 
data. Data collection and analysis will involve an interac-
tive process, whereby initial transcripts will be reviewed by 
other members of the research team, and modifications 
and additions to some questions made. We anticipate 
analysis of qualitative data will be completed by October 
2020.
Interviews and focus groups with patients on haemodialysis and 
nursing staff
Authors ED, AV, PB and KD will conduct separate focus 
groups or semistructured interviews with patients or 
nurses at each participating site. Focus groups will aim 
to have six to eight participants in each and last approx-
imately 90 min. This method of data collection was 
selected as an option as it is expected to provide opportu-
nity to harness group dynamics (eg, brainstorming, clari-
fication of ideas and differences of opinion) for detailed 
discussion among patients or nursing staff. Focus groups 
will take place in a private room at the hospital or dialysis 
unit. A tablet with sample versions of the EQ- 5D- 5L and 
IPOS- Renal surveys will be available during focus groups 
and interviews to aid discussion, if necessary. If a patient 
or nurse is unable to attend a focus group, they will have 
the opportunity of participating in a semistructured inter-
view with a member of the research team, in person or 
via telephone. Semistructured question guides for patient 
and nurse interviews and focus groups are provided in 
online supplemental files 1 and 2). These include some 
set/specific questioning by the researcher regarding the 
feasibility and acceptability topics of interest, as well as 
opportunity for questions and prompts that are guided by 
participants’ responses. These were informed by a litera-
ture review of previous research on PROMs collection23 
and discussion among the multidisciplinary research 
team, including nephrologists, nurses and consumers.
Prior to the commencement of focus groups and inter-
views, participants will be reminded of the aim of the 
project and their right to withdraw at any time. Inter-
views and focus groups will not commence until partic-
ipants’ written informed consent is obtained. They will 
be audio recorded with participants’ consent and tran-
scribed verbatim. Participants will be made aware that 
only researchers involved in the qualitative evaluation 
of SWIFT will have access to their transcripts and that 
de- identified versions and exemplar quotes will be viewed 
by other project staff and will form the basis of publica-
tions and presentations.
Interviews with nephrologists
Author AV will conduct semistructured interviews with 
nephrologists either via telephone or face- to- face at a 
mutually convenient time and location (eg, office or 
meeting room in the hospital or dialysis units). The inter-
view guide is provided in online supplemental file 3) and 
was informed by relevant literature and discussion among 
the research team. Interviews will be audio recorded and 
transcribed verbatim. Interviews will not commence until 
participants’ written informed consent is obtained.
One strength of this pilot study is the sampling of 
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nephrologists. These methods of interview and focus 
groups will provide sufficient data to elicit their expe-
riences and perspectives regarding the intervention 
process, acceptability and feasibility, and perceived 
impacts on patient care and outcomes in order to inform 
the main trial. We anticipate this will require at least 20 
participants in total, 10–12 from the intervention group 
and 8–10 from the control group.
Data analysis
The data will be entered into HyperRESEARCH software 
and analysed thematically.24 Thematic analysis enables 
the identification and analysis of themes across qualita-
tive data, to reveal implicit meaning and phenomena in 
relation to the research question. Identification of themes 
will be guided by NPT, an analytic framework which can 
explain how technology is implemented, embedded and 
integrated into healthcare settings, including factors that 
promote or inhibit ‘normalisation’ into practice.25 NPT 
consists of four constructs:
1. Coherence: how people individually and collectively 
understand and make sense of implementing a new 
practice.
2. Cognitive participation: how people build and sustain 
engagement with new practice.
3. Collective action: how people enact the new practice.
4. Reflexive monitoring: how people formally and infor-
mally appraise and understand the effects of the new 
practice once in use.26
All transcripts will first be coded inductively by two 
researchers, including the identification of the perceived 
impacts of e- PROMS collection and feedback on patient 
care and outcomes. NPT will then be used as a guide to 
deductively identify additional/alternative themes, to 
examine how e- PROMs become ‘normalised’ into dial-
ysis units, including the barriers and facilitators. Codes 
will be grouped into themes and subthemes and rela-
tionships among them identified. Data of each partic-
ipant group (patients, nurses, nephrologists) will be 
analysed separately until data saturation. Derived themes 
will be reviewed by other members of the research team 
throughout the analysis process as researcher triangu-
lation, to ensure the full range and depth of data are 
reflected in the findings.18 Comparisons will be drawn 
between nurse, nephrologist and patient responses. A 
summary of themes will be provided to participants for 
comment and feedback (member checking) to ensure 
their views are captured and accurately reflected in final 
analysis and reporting of results.
Patient and public involvement
Prior to the pilot, two patients in a local haemodialysis unit 
completed the e- PROMs while undergoing dialysis and 
were observed by two members of the research team who 
took note of relevant environmental factors, use of tablet 
stands/cases and patient–nurse interactions. A consumer 
partner (carer of person receiving haemodialysis) and 
member of the SWIFT Management Committee provided 
input throughout the development of the project design 
and qualitative study protocol, including to the interview 
and focus group question guides. A group of consumers 
from participating pilot sites will have opportunity to 
review and interpret findings of the qualitative study, 
create patient- version summaries of these and assist in 
refining the intervention and design of the SWIFT main 
trial. The Better Evidence And Translation–Chronic 
Kidney Disease ‘Consumers in Research Programme’ will 
train the consumers, with additional support provided 
through the Australian Clinical Trials Alliance Consumer 
and Community Involvement workshop (https:// clin ical 
tria lsal liance. org. au/ events- forums/ consumer- commu-
nity- involvement- in- clinical- trials- acta- training- workshop- 
3/). We will also provide specific individual training and 
mentorship in the analysis of qualitative data by qualita-
tive researchers on the investigator team.
DISCUSSION
This study aims to gain rich and in- depth insights from 
key stakeholders about the SWIFT intervention processes, 
acceptability and feasibility, and impact on patient care 
and outcomes. To ensure the successful implementation 
of an e- PROMs system and use of patient data, under-
standing factors such as resourcing, technological issues, 
timing and setting of data collection and appropriate 
feedback mechanisms, from the perspectives of renal 
medical staff and patients, will be imperative. Themes 
identified from the qualitative evaluation of the SWIFT 
pilot will inform and refine the intervention for the main 
trial, based on the views of those providing and receiving 
clinical care.
From the patient perspective, the feasibility of various 
data collection timepoints will be important to explore (ie, 
before, during or after a dialysis session). Surroundings 
and privacy in the dialysis unit, presence of blood lines 
and patients’ handedness need to be considered. Patient 
confidence with electronic devices and their experience 
completing the e- PROMs tools will be explored to under-
stand the user experience with the device, including its 
logic, item presentation and navigation prompts. The 
timing of data collection also raises the question of how 
the patient’s state and symptoms at the time may influ-
ence reports and consideration of the prescribed recall 
periods in surveys. Interviews and focus groups will also 
reveal patients’ views and experiences of changes (or 
not) in clinical care and management based on feedback 
of results to their renal team and perceived impacts on 
quality of life.
The views of dialysis nurse unit managers and nursing 
staff will be important to understand uptake of the 
data collection process, resourcing requirements and 
administration and information technology (IT) issues 
associated with e- PROMs collection, ‘on the ground’ in 
dialysis units. Staff familiarity and confidence with elec-
tronic devices may be factors that influence uptake and 
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explore IT aspects, staff support needs and potential solu-
tions based on their experiences. To mitigate challenges 
that may hinder the implementation of e- PROMs collec-
tion, IT issues such as method of patient identification 
and internet availability in dialysis units need to be under-
stood. Moreover, patient- reported outcomes may be influ-
enced by how nurses administer the data collection tools, 
deliver instructions and provide assistance (or not) to 
patients during reporting.
A successful feedback mechanism is imperative to the 
usefulness of collected PROMs to improving patient 
care and outcomes. A feedback process includes identi-
fying an optimal mode of notification and communica-
tion of results to clinical teams (eg, email, printed data 
inserted into clinical notes in dialysis unit or a patient- 
initiated log- in system) and timing of delivery of patient- 
reported outcomes to clinicians to ensure accessibility 
and relevance at the patient’s next clinical encounter and 
opportunity for timely clinical action. Preferences for 
these are likely to be influenced by complex system and 
operational differences across hospital and dialysis units. 
It is also important to explore clinician preferences for 
the presentation of results (eg, providing all of a patient’s 
symptom scores, or only those identified as burdensome) 
and how PROMs collection may affect or be affected by 
centres’ existing procedures for responding to problem-
atic symptoms as part of standard care. We acknowledge 
that our data collected on implementation of e- PROMs 
capture and feedback within the context of a randomised 
trial, may not necessarily reflect routine care.
While haemodialysis maintains life, patients often 
live with substantial physical and psychosocial symptom 
burden. Consistent with the increased emphasis on 
patient- centred care, SWIFT will address patient- 
prioritised issues and outcomes that have previously 
been overlooked. Qualitative evaluation of the SWIFT 
pilot study will provide invaluable insights from those 
ultimately responsible for the implementation and use 
of e- PROMs and will inform a large multicentre registry- 
based randomised controlled trial to evaluate whether 
symptom monitoring with feedback improves care and 
outcomes for people receiving haemodialysis.
ETHICS AND DISSEMINATION
Ethics approval for SWIFT was obtained from the rele-
vant hospital Human Research Ethics Committees 
(HREC/18/CALHN/481; HREC/MML/54599). Find-
ings from the SWIFT pilot will be presented at scientific 
meetings and prepared for publication in peer- reviewed 
journals. Participating units will be provided a summary 
of the findings, including patient- facing versions co- devel-
oped with consumers.
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